Non-Routine EEG Recording Guideline

1. Purpose of the Guideline
2. Introduction to the Guideline
3. Limits of the Guideline
4. Electrodes
   (i) Electrode Placement
   (ii) Electrode Choice
   (iii) Electrode Impedance
5. Pre-test Checks
   (i) Calibration
   (ii) Biological Calibration
   (iii) All Electrode Check
6. Recording
   (i) EEG Monitoring in Critical Care Environments
      a) Electrode Placement
      b) Electrical Safety
      c) Filter Settings
      d) Sensitivity
      e) Calibration
      f) Patient Information
      g) Annotation
      h) Montages
      i) Additional Physiological Measurements
      j) Length of Recording
      k) Stimulation
      l) Activation
   (ii) EEG in Suspected Electro Cerebral Silence
      a) Electrode Placement
      b) Electrical Safety
      c) Filter Settings
      d) Sensitivity
      e) Calibration
      f) System Integrity
      g) Patient Information
      h) Annotation
      i) Montages
      j) Other Physiological Measurements
k) Length of Recording
i) Stimulation

7. Post-recording checks
   (i) Biological Calibration
   (ii) All Electrode Check
   (iii) Calibration

8. Factual Report Writing

9. References

Appendix 1 – Stakeholders
Additional Readings

Disclaimer and Copyright
1. PURPOSE
These guidelines have been prepared to offer guidance towards best practice for recording a non routine EEG within Australia.

2. INTRODUCTION
The following guidelines should be considered as minimum standards to record a non routine EEG in clinical practice. These non routine EEGs include EEG monitoring in critical care environments, EEG in suspected Electro-Cerebral Silence (ECS) and other EEGs outside the routine setting. They have been prepared by a sub-committee governed by ANTA Inc. and have been presented to stakeholders within the field of Clinical Neurophysiology in Australia (see Appendix 1). A review of international guidelines was made to ensure that this ANTA Inc. Guideline is consistent with worldwide standards.

3. LIMITS OF THE GUIDELINE
This guideline relates to non routine EEG for children and adults including EEGs performed in critical and intensive care settings and EEG recordings performed in the clinical setting of electro-cerebral silence. This guideline does not relate to recording neonatal EEGs or in the operating theatre.

4. ELECTRODES
(i) Electrode Placement
(ii) Electrode Choice
(iii) Electrode Impedance

Refer to the ANTA Inc. Routine EEG Recording Guideline\(^1\).

5. PRE-TEST CHECKS
(i) Calibration
(ii) Biological Calibration
(iii) All electrode Check

Refer to the ANTA Inc. Routine EEG Recording Guideline\(^1\).

6. RECORDING

(i) EEG MONITORING IN CRITICAL CARE ENVIRONMENTS

a) Electrode Placement
When possible, electrode positions should be measured in accordance with ‘The 10-20 Electrode System of the International Federation’\(^2\) or a modified version if required due to placement restrictions. If the head cannot be measured due to clinical constraints this information should be made available to the reporting clinician. When an electrode placement is changed the placement of the corresponding electrode over the opposite hemisphere should be changed to
maintain symmetry \(^{(1)}\). Any deviation from the placement system should also be documented e.g. in the instance of a surgical wound at a measured electrode placement.

b) Electrical Safety
Electrical safety precautions in accordance with the ‘Australian and New Zealand Standards: Guide to the Safe Use of Electricity in Patient Care AS2500:2004 Electrical Installations - Patient Areas’ should be adhered to \(^{(3)}\). All recording equipment should be connected via an isolated transformer.

c) Filter Settings
Refer to the ANTA Inc. Routine EEG Recording Guideline \(^{(1)}\).

Notch Filter
A 50Hz notch filter should only be used after all other methods of eliminating mains interference, such as reduction of electrode impedances and/or appropriate earthing and positioning or removal of surrounding mains equipment, have been fully explored \(^{(4)}\). If a notch filter is used this should be documented within the factual report. A period of recording without the 50Hz notch filter should be recorded if the 50Hz notch filter is used.

d) Sensitivity
Refer to the ANTA Inc. Routine EEG Recording Guideline \(^{(1)}\).

e) Calibration
The square wave calibration should represent machine parameters (filters and sensitivity settings) used during the EEG recording \(^{(1)}\).

f) Patient Information
Additional patient and clinical information is required for recording EEG in the critical care unit which should include but not be limited to \(^{(5)}\):
- All medications and dosages including sedative agents and any agents introduced during the recording period
- How long prior to the EEG sedative agents were ceased (if applicable)
- Glasgow Coma Scale (GCS) at the time of the recording
- Artificial ventilation
- Body temperature.

Refer to the ANTA Inc. Routine EEG Recording Guideline \(^{(1)}\) for minimum patient information – section 6(i).

g) Annotations
Continuous observation and annotation are important and should include where appropriate but not be limited to \(^{(6)}\):
- Change to or the administration of medication during the recording including dosage
• Nursing intervention/patient interaction
• Environmental stimuli such as ward noise
• Heart rate, saturation of peripheral oxygen (SpO₂) level and blood pressure at regular intervals and for any noted changes
• Any intentional stimulation including the nature of the stimulation, both when it is applied and ceased
• Any clinical features/events or changes to the patient's state.

h) Montages
Refer to the ANTA Inc. Routine EEG Recording Guideline.

i) Additional Physiological Measurements
The electrocardiogram (ECG) should be recorded for recognition of ECG artefact for recording at these screen sensitivities. Other polygraphic channels such as Electromyogram (EMG), Electro-oculogram (EOG), respiration and movement may also be included where appropriate.
Refer to the ANTA Inc. Additional Physiological Measurements Recording Guideline.

j) Length of Recording
Refer to the ANTA Inc. Routine EEG Recording Guideline.

See further information in section 6(ii) for montages and recording time in the case of suspected electro-cerebral silence.

k) Stimulation
Any non-responsive patient should be stimulated during the EEG recording to determine the clinical and EEG reactivity to the stimulus. In patients who are not sedated this has proven to yield prognostic value.
Stimulation should include but not be limited to:

Auditory Stimulation

• Loud claps should be performed close to both sides of the patient’s head for auditory stimulation. It is important to stimulate bilaterally as there may be blockage of an ear canal or unknown reduced hearing on one side. A minimum of 20 seconds should be left between each set of claps to determine any developing changes to the EEG that may occur.
• The patient’s first name or preferred name (if known) should be called loudly next to each of the patient’s ears. There should be a 20 second pause between side stimulation.
Painful Stimulation \(^{(7, 8)}\)
- Painful stimulation should be applied on either side of the body each for 5 seconds with a 20 second pause between each stimulus. Both sides should be stimulated separately to take into account any unknown hemiplegia or hemiparesis. Examples of painful stimulation include:
  - Pressure applied to the nail bed of the thumb or great (big) toe
  - Trapezius squeeze
  - Sternal rub (midline only).

Central Stimulation \(^{(5, 8)}\)
- If the patient is intubated, suction of the patient’s oral airway performed by attending nursing or medical staff can be useful.

l) Activation Procedures
Activation procedures as per ANTA Inc. Routine EEG Guidelines \(^{(1)}\) should be performed if the patient is able to co-operate.
For unresponsive patients the following activations may be useful
- a period of assisted eyes open for 5-10 seconds
- photic stimulation

(ii) EEG IN SUSPECTED ELECTROCEREBRAL SILENCE (ECS) \(^{(5, 8, 9)}\)

a) Electrode Placement
When possible, placement should not differ from the routine EEG practice.
Refer to the ANTA Inc. Routine EEG Recording Guideline \(^{(1)}\). See EEG Monitoring in Critical Care Environments point 6.(i).(a) above.

b) Electrical Safety
As per EEG Monitoring in Critical Care Environments. See 6 (i)(b) above.

c) Filter Settings
High frequency filters (HFF) should not be set below 30Hz and low frequency filters (LFF) should not be set above 1Hz to avoid attenuation of low voltage slow or fast activity \(^{(8)}\).

- Notch Filter
A 50Hz notch filter should only be used after all other methods of eliminating mains interference, such as reduction of electrode impedances and/or appropriate earthing and positioning or removal of surrounding mains equipment, have been fully explored \(^{(4)}\). If a notch filter is used this should be documented within the factual report. A period of recording without the 50Hz notch filter should be recorded if the 50Hz notch filter is used.

d) Sensitivity
The EEG in cases of suspected ECS should be recorded at a sensitivity of 2µV/mm for a minimum of 30 minutes \(^{(2, 8)}\).
e) Calibration
The square wave calibration should represent machine parameters (filters and sensitivity settings) used during the EEG recording (8). In suspected ECS it is therefore appropriate to calibrate at 2 μV/mm.

f) System Integrity
The integrity of the recording system should be confirmed when there is evidence of electro-cerebral silence. Each electrode should be tapped by the technologist at the beginning of the recording to create an artefact potential to ensure connection to the head box is intact (8).

g) Patient Information
As per EEG Monitoring in Critical Care Environments. See 6 (i)(f) above.

h) Annotations
As per EEG Monitoring in Critical Care Environments. See 6 (i)(g) above.

i) Montages
Montages for recording in suspected ECS should represent inter-electrode distances of 10cm or more. Montages comprised of double distance electrode channels should be used in addition to existing montages (8).

Example of wideplacement EEG recording montage

<table>
<thead>
<tr>
<th>Anterior to posterior</th>
<th>Transverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fp2 – C4</td>
<td>F8 – Fz</td>
</tr>
<tr>
<td>C4 – O2</td>
<td>Fz – F7</td>
</tr>
<tr>
<td>F4 – P4</td>
<td>F4 – F3</td>
</tr>
<tr>
<td>Fp1 – C3</td>
<td>A2 – C4</td>
</tr>
<tr>
<td>C3 – O1</td>
<td>C4 – C3</td>
</tr>
<tr>
<td>F3 – P3</td>
<td>C3 – A1</td>
</tr>
<tr>
<td></td>
<td>T4–Cz</td>
</tr>
<tr>
<td>Fp2 – T4</td>
<td>Cz–T3</td>
</tr>
<tr>
<td>T4 – O2</td>
<td></td>
</tr>
<tr>
<td>F8 – T6</td>
<td>T6 – Pz</td>
</tr>
<tr>
<td></td>
<td>Pz – T5</td>
</tr>
<tr>
<td>Fp1 – T3</td>
<td>P4 – P3</td>
</tr>
<tr>
<td>T3 – O1</td>
<td></td>
</tr>
<tr>
<td>F7 – T5</td>
<td></td>
</tr>
<tr>
<td>Fz – Pz</td>
<td></td>
</tr>
</tbody>
</table>

ECG
Respiration and movement/EMG where applicable
j) Additional Physiological Measurement
The electrocardiogram (ECG) should be recorded for recognition of ECG artefact for recording at these screen sensitivities. Other polygraphic channels such as EMG, EOG, respiration and movement may also be included where appropriate\(^8\).
Refer to the ANTA Inc. Additional Physiological Measurements Recording Guideline\(^9\).

k) Length of Recording
EEG recordings in cases of suspected ECS should be no less than 30 minutes in duration\(^8\).

l) Stimulation
Refer to section 6.(i). (g) 'Stimulation'.

7. POST-RECORDING CHECKS

(i) Biological Calibration
(ii) All Electrode Check
(iii) Calibration

Refer to the ANTA Inc. Routine EEG Recording Guideline\(^1\).

8. FACTUAL REPORT

Refer to the ANTA Inc. Routine EEG Recording Guideline\(^1\).
9. REFERENCES


Additional Readings


Appendix 1 – Stakeholders

Stakeholders
- ANTA Inc. Members
- Document Development Committee
- Document Development Committee Advisory Group
- Other interested parties

Original Document
Document Development Committee
Mary Lynch, Joanne Wex, Holly Campbell, Anna Exley, Santhi Chigurupati, Malcolm Corkhill, Kate Martin, Emma Fetherston, Amy Lofts, Fred Tremayne, Vicky Grant

Advisory Committee
The document development committee identified a group of key stakeholders to view the draft documents for feedback. The advisory group was made up of technologists, scientists and neurologists working in the neurophysiology industry around Australia. The comments from this group were considered, compared against the reference material and included where appropriate.

Members Feedback
On completion of the final draft the document was put out to all members of ANTA Inc. for feedback. The comments from members were considered, compared against the reference material and included where appropriate.

Guideline Acceptance
This Guideline was accepted by members in July 2014.

Amendments
2016 May  Disclaimer and Copyright statements added.
Disclaimer

(i) The use of information and data contained within this guideline is at your sole risk for ANTA Inc. will not be liable

(ii) If you rely on the information from this guideline you are responsible for ensuring by independent verification its accuracy, currency or completeness. You are also responsible for making sure it meets your specific requirements. ANTA Inc. does not warrant or take responsibility for the accuracy, currency or completeness.

(iii) You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.

(iv) The information and data in this guideline is subject to change without notice.

(v) This guideline may include links to websites. These linked websites will have their own terms and conditions of use and you should read and familiarise yourself with these terms and conditions.

(vi) ANTA Inc. may revise this disclaimer at any time including by updating this page

Copyright ©

(i) You are welcome to use this guideline and the information contained on it.

(ii) All material in this guideline is protected in Australia under the Copyright Act 1968 (Cth).

(iii) You are permitted to either electronically save or print out parts of this guideline for your own information, research or study but are prohibited from using the information for any commercial purpose.

(iv) You are not permitted to modify copy in any way from the form in which it appears in this guideline.

(v) You must not republish any material contained in this guideline either on another web site, or in any other medium, print, electronic or otherwise without seeking permission to do so. Subject to Copyright Act 1968 all such use may only be authorised in writing by the copyright owner (ANTA Inc.)

(vi) Apart from this provision and uses permitted under the Copyright Act 1968, all other rights are reserved.